Researchers have found that antibiotic minocycline can increase the lifespan of aged roundworms by preventing the build-up of proteins, revealing a protective mechanism that could be used to help prevent age-related neurodegenerative diseases in humans.
Protein aggregation has been known to cause several progressive age-related brain diseases, including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and prion disease.
The study, led by a team from the Scripps Research in the US, showed that minocycline prevents this build-up even in older animals with age-impaired stress-response pathways.
The number of proteins in a cell is balanced by the rate of protein manufacture and disposal, called proteostasis. As we age, proteostasis becomes impaired.
"We have identified minocycline as a drug that can extend lifespan and improve protein balance in already-ageing worms," said Michael Petrascheck, Associate Professor at the Scripps Research.
"Our study reveals how minocycline prevents protein aggregation and lays the foundation for drug-development efforts aimed at optimising this already-approved drug for a range of neurodegenerative diseases."
For the study, reported in the journal eLife, the team first tested 21 different molecules known to extend lifespan in young and old Caenorhabditis elegans (C. elegans) worms.
They found that all of these molecules prolonged the lives of young worms; however, the only drug that worked on older worms was minocycline.
To find out why, they treated young and old worms with either water or minocycline and then measured two proteins called a-synuclein and amyloid-ß -- known to build up in Parkinson's and Alzheimer's diseases, respectively.
Regardless of the worms' age, those treated with minocycline had reduced aggregation of both proteins as they grew older without even the activation of stress responses.
It is because minocycline directly affects the protein-manufacturing machinery of the cell, known as the ribosome. This was true in worms as well as in mouse and human cells, the researchers said.
--IANS
rt/mag/mr
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
